The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2009Exploring Curcumin and Curcumin Derivatives as Putative Epigenetic Target of Histone Deacetylase (HDAC) Inhibition in Parkinson's Disease
Objective/Rationale:
Our project is to explore cutting-edge nano- biotechnology advances in formulating curcumin extracted from Curry as potential drug candidates in treatment of Parkinson disease... -
Therapeutics Development Initiative, 2009Effect of Novel Neuronal Nicotinic Receptor Compounds on Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
Objective/Rationale:
The idea that compounds targeting neuronal nicotinic receptors may be useful for the treatment of L-dopa-induced abnormal involuntary movements (AIMs), or dyskinesias, stemmed from... -
Therapeutics Development Initiative, 2009Assessment of the Therapeutic Efficacy of Progranulin in a Sub-chronic Small Model of Parkinson's Disease
Objective/Rationale:
Progranulin (PGRN), a protein found in the brain, is thought to promote the survival and health of brain cells. Neurodyn Inc. has discovered PGRN to have disease-modifying effects... -
Therapeutics Development Initiative, 2009Validation of LRRK2 as a Drug Target for Treatment of Parkinson's Disease Using Antisense Technology
Objective/Rationale:
Missense mutations in leucine-rich repeat serine/threonine-protein kinase (Lrrk2) are linked/associated with dominantly inherited, late-onset Lewy body Parkinson's disease (PD)... -
Therapeutics Development Initiative, 2009Pre-clinical Development of a Parkinson's Disease Therapy Using a Glucagon-Like Peptide (GLP)-1 Receptor Agonist
Objective/Rationale:
The Glucagon-Like-Peptide-1 (GLP-1) receptor agonist, exendin-4 (exenatide injection; brand name Byetta) is an FDA-approved, first-in-class treatment for patients with Type 2... -
Therapeutics Development Initiative, 2009Distribution of a Dominant-negative Inhibitor of Tumor Necrosis Factor
Objective/Rationale:
The blood-brain barrier (BBB) allows only a small fraction of systemically administered small-molecule drugs and even fewer biopharmaceuticals developed for disorders of the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.